- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
MIRA
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
MIRA Pharmaceuticals, Inc. Common Stock · Healthcare · Drug Manufacturers - General
Latest close
0.79 USD
-10.2%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -26.7% below the Trend Line and sits at 1.2% of its 52-week range. The latest completed week returned -10.2%, after a -16.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 48/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.
Setup score
16
out of 100
Latest Close
0.79 USD
31 Jul 2026
1W Return
-10.2%
latest completed week
4W Return
-16.2%
short-term follow-through
12W Return
-19.8%
quarterly tape
Trend Breadth
48.1%
25 of 52 weeks active
Volume Ratio
0.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-10.2%
Latest completed week; four-week move -16.2%.
Indicator stack
26/10
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
48/100
20 relevant articles in the latest sentiment read.
Event risk
11d
Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -26.7% below the Trend Line and sits at 1.2% of its 52-week range. The latest completed week returned -10.2%, after a -16.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0212-week average 0.02
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -16.2% over four weeks, -19.8% over 12 weeks, and -48.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year25
Trend breadth48.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.55Latest activity-pressure read.
Pressure change-382.3%Four-week change in activity pressure.
Leadership-41.96Latest relative-leadership reading.
RS change-13.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 61%
Model confidence 58%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength79/100Blend of value, momentum, and quality. Underlying universe rank 22; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality63/100Profitability and accounting quality. Underlying universe rank 38; rank 1 is best.
Momentum65/100Medium-term price momentum. Underlying universe rank 36; rank 1 is best.
Growth65/100Revenue and earnings growth. Underlying universe rank 36; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -13.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -18.9% Net share repurchases relative to market value.
- Shareholder yield
- -18.9% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment48/100
Weighted news tone is neutral across 20 relevant articles.
2 positive · 14 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-67.7%Distance below the 52-week high.
13-week volatility5.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher11 of 2615 weeks finished lower.
Best week+12.0%Week of 27 Mar.
Worst week-24.0%Week of 20 Mar.
Latest week-10.2%Week of 31 Jul.
Shape of recent returns
Strong gains7
Modest gains4
Flat weeks0
Modest losses6
Sharp losses9
Recent vol5.4%13-week weekly-return volatility.
Base vol8.3%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew6.4% / -6.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Drug Manufacturers - General
4-week rank19 / 20
Group average-4.6%
Trend breadth50.0%
Trend50.0%active weekly trend signals
MD65.0%positive activity pressure
RS45.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape19/100
Trend, activity pressure, participation, and risk combine to a 19/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.02; No reversal markers Factors67/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 91 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment48/100Weighted news tone is neutral across 20 relevant articles.
MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA Insiders50/100No recent insider transaction evidence is stored.
Earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 0.79 USD | -10.2% | 1.08 USD | 1.53 USD | -0.55 | -41.96 | 270.1K | Off |
| 24 Jul 2026 | 0.88 USD | -8.1% | 1.10 USD | 1.56 USD | -0.37 | -36.04 | 286.2K | Off |
| 17 Jul 2026 | 0.96 USD | 3.8% | 1.12 USD | 1.57 USD | -0.10 | -32.63 | 392.2K | Off |
| 10 Jul 2026 | 0.92 USD | -2.1% | 1.15 USD | 1.57 USD | -0.18 | -38.87 | 283.3K | Off |
| 3 Jul 2026 | 0.94 USD | -6.5% | 1.17 USD | 1.57 USD | -0.11 | -37.00 | 158.8K | Off |
| 26 Jun 2026 | 1.01 USD | 6.0% | 1.18 USD | 1.58 USD | -0.10 | -32.59 | 563.4K | Off |
| 19 Jun 2026 | 0.95 USD | 1.3% | 1.20 USD | 1.58 USD | -0.11 | -39.76 | 372.4K | Off |
| 12 Jun 2026 | 0.94 USD | -6.0% | 1.21 USD | 1.59 USD | -0.16 | -39.52 | 405.8K | Off |
| 5 Jun 2026 | 1.00 USD | -5.7% | 1.23 USD | 1.59 USD | -0.27 | -34.76 | 655.3K | Off |
| 29 May 2026 | 1.06 USD | 6.9% | 1.24 USD | 1.60 USD | -0.44 | -34.67 | 1.1M | Off |
| 22 May 2026 | 0.99 USD | 3.0% | 1.26 USD | 1.60 USD | -0.74 | -37.73 | 331.6K | Off |
| 15 May 2026 | 0.96 USD | -2.4% | 1.28 USD | 1.60 USD | -0.83 | -39.35 | 600.4K | Off |
| 8 May 2026 | 0.99 USD | -5.1% | 1.30 USD | 1.61 USD | -0.89 | -38.79 | 573.6K | Off |
| 1 May 2026 | 1.04 USD | -1.0% | 1.31 USD | 1.61 USD | -0.98 | -32.60 | 658.3K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.